Cargando…

Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC

Detalles Bibliográficos
Autor principal:	Lamb, Yvette N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8613116/ https://www.ncbi.nlm.nih.gov/pubmed/34694530 http://dx.doi.org/10.1007/s11523-021-00853-y

Ejemplares similares

Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
por: Lamb, Yvette N.
Publicado: (2021)

Osimertinib for Previously Treated Patients With Advanced EGFR T790M Mutation-Positive NSCLC: Tolerability and Diagnostic Methods From an Expanded Access Program
por: Santos, Edgardo S., et al.
Publicado: (2018)

Switching from first or second generation EGFR-TKI to osimertinib in EGFR mutation-positive NSCLC
por: Imamura, Fumio, et al.
Publicado: (2020)

Correction to: Osimertinib as first-line therapy in advanced NSCLC: a profile of its use
por: Scott, Lesley J.
Publicado: (2018)

Osimertinib in combination with bevacizumab in EGFR-Mutated NSCLC with leptomeningeal metastases
por: Jiang, Tao, et al.
Publicado: (2020)

Osimertinib and pterostilbene in EGFR-mutation-positive non-small cell lung cancer (NSCLC)
por: Bracht, Jillian Wilhelmina Paulina, et al.
Publicado: (2019)

Efficacy and safety of osimertinib in treating EGFR‐mutated advanced NSCLC: A meta‐analysis
por: Yi, Lilan, et al.
Publicado: (2019)

Publisher Correction: The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M
por: Huang, Yen-Hsiang, et al.
Publicado: (2021)

EGFR mutation genotypes affect efficacy and resistance mechanisms of osimertinib in T790M-positive NSCLC patients
por: Zheng, Qiufan, et al.
Publicado: (2020)

Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases
por: Zheng, Mei-Mei, et al.
Publicado: (2022)

Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study
por: Ji, Jingran, et al.
Publicado: (2023)

Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib
por: Hochmair, Maximilian J., et al.
Publicado: (2018)

Osimertinib – effective treatment of NSCLC with activating EGFR mutations after progression on EGFR tyrosine kinase inhibitors
por: Skrzypski, Marcin, et al.
Publicado: (2017)

Life-Threatening Myositis in a Patient With EGFR-Mutated NSCLC on Osimertinib: Case Report
por: Crowley, Fionnuala, et al.
Publicado: (2021)

Author Correction: Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer
por: Chmielecki, Juliann, et al.
Publicado: (2023)

Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study
por: Cheng, Ying, et al.
Publicado: (2021)

Monitoring of Plasma EGFR Mutations during Osimertinib Treatment for NSCLC Patients with Acquired T790M Mutation
por: Watanabe, Kana, et al.
Publicado: (2023)

Effectiveness of afatinib in an NSCLC patient with EGFR mutation and early progression to osimertinib: a case report
por: Nozaki, Koichiro, et al.
Publicado: (2022)

Incidence of Bone Metastases and Skeletal-Related Events in Patients With EGFR-Mutated NSCLC Treated With Osimertinib
por: Brouns, Anita J.W. M., et al.
Publicado: (2023)

Case Report: Durable therapy response to Osimertinib in rare EGFR Exon 18 mutated NSCLC
por: Cekay, Michael, et al.
Publicado: (2023)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
por: Cui, Qingli, et al.
Publicado: (2022)

Correction to: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases
por: Tan, Wan-Ling, et al.
Publicado: (2018)

A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study
por: Chihara, Yusuke, et al.
Publicado: (2022)

Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
por: La Monica, Silvia, et al.
Publicado: (2017)

Osimertinib and Bevacizumab Cotreatment for Untreated EGFR-Mutated NSCLC With Malignant Pleural or Pericardial Effusion (SPIRAL II): A Single-Arm, Open-Label, Phase 2 Clinical Trial
por: Hibino, Makoto, et al.
Publicado: (2022)

Comparation of EGFR-TKI (EGFR tyrosine kinase inhibitors) combination therapy and osimertinib for untreated EGFR-mutated advanced non-small cell lung cancers: A systematic review and network meta-analysis
por: Lei, Yang, et al.
Publicado: (2023)

Durable Response of Leptomeningeal Disease With Osimertinib and Pemetrexed in EGFR-Mutated Metastatic NSCLC: A Case Report
por: Merkhofer, Cristina M., et al.
Publicado: (2021)

Osimertinib for an Advanced NSCLC Patient with Two Common EGFR Mutations and a Concomitant MET Exon 14 Skipping Mutation: A Case Report
por: Liu, Zhicong, et al.
Publicado: (2023)

Intrinsic Resistance to Osimertinib in EGFR Mutated NSCLC Cell Lines Induced by Alteration in Cell-Cycle Regulators
por: Volta, Francesco, et al.
Publicado: (2023)

Efficacy of Osimertinib in NSCLC Harboring Uncommon EGFR L861Q and Concurrent Mutations: Case Report and Literature Review
por: Lin, Ruiting, et al.
Publicado: (2021)

The Role of Neutrophil-to-Lymphocyte Ratio in Advanced EGFR-Mutant NSCLC Patients Treated with First-Line Osimertinib
por: Chen, Kuan-Chih, et al.
Publicado: (2023)

Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib
por: Yamamoto, Nobuyuki, et al.
Publicado: (2019)

Therapeutic effect of osimertinib plus cranial radiotherapy compared to osimertinib alone in NSCLC patients with EGFR-activating mutations and brain metastases: a retrospective study
por: Zhai, Xiaoyang, et al.
Publicado: (2021)

Osimertinib Improves overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastases
por: Ye, Qiuyue, et al.
Publicado: (2023)

Correction to: Nintedanib: A Review in Fibrotic Interstitial Lung Diseases
por: Lamb, Yvette N.
Publicado: (2021)

RELAY+: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients With EGFR-Mutated Metastatic NSCLC
por: Nishio, Makoto, et al.
Publicado: (2022)

Observational study of rebiopsy in EGFR-TKI-resistant patients with EGFR mutation-positive advanced NSCLC
por: Koyama, Kenichi, et al.
Publicado: (2022)

Effectiveness and safety of osimertinib in patients with metastatic EGFR T790M-positive NSCLC: An observational real-world study
por: Cao, Yabing, et al.
Publicado: (2019)

Correction: Potential benefit of osimertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer
por: Yi, Yali, et al.
Publicado: (2022)

Abivertinib in patients with T790M‐positive advanced NSCLC and its subsequent treatment with osimertinib
por: Wang, Hanping, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_t954iko94a0d3mcdgiv9bnnarq